⚠ AI Risk Brief Interpretation layer — deterministic data below

BDX added AI governance risk and Waters merger execution risks while strengthening cybersecurity and regulatory disclosure.

Direction ↑ More concerning

ThemesArtificial Intelligence Regulatory & Legal Cybersecurity

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

🟢 New in Current Filing Disclosure change10/10

The development, deployment and use of AI in our products and business operations generally could result in regulatory action, legal liability, operational challenges or reputational harm and our failure to adapt to medical technology industry trends and developments related to AI in a timely manner (or at all) could adversely affect our business, financial condition, results of operations and cash flows.

Read full text

We have integrated (and expect to continue to integrate) AI into our products and business operations generally. We also expect to continue to develop future uses of AI and expand our existing AI capabilities to include agentic solutions, as well as pursue new AI technology partnerships with third parties. The development, deployment and use of AI (particularly generative AI) is in the early stages and presents various risks, including from confidentiality, privacy, data protection, cybersecurity and compliance perspectives, and raises intellectual property issues and legal, regulatory, reputational ethical, operational, technological and other concerns (see, “Our operations are dependent in part on patents and other intellectual property assets” and “Cybersecurity incidents and breaches or breakdowns of our information and technology systems or infrastructure could have a material adverse effect on our operations” elsewhere in this Item 1A, Risk Factors). Additionally, if we do not effectively adopt and integrate AI into innovative, market-differentiated products in a timely manner, our competitive position could be adversely affected.

🟢 New in Current Filing The proposed combination of our Biosciences and Diagnostic Solutions business with Waters may not be completed, on the currently contemplated timeline or at all. 🔒

🟢 New in Current Filing The announcement and pendency of the combination of our Biosciences and Diagnostic Solutions business with Waters could cause disruptions in our business. 🔒

🟢 New in Current Filing We may not realize some or all of the expected benefits of the combination of our Biosciences and Diagnostic Solutions business with Waters. 🔒

And 20 more changes in the full comparison.

23 more changes in this filing

Full diff access, historical comparisons, and cross-company signal tracking.

Get Pro access Already a Pro subscriber? View full diff →